Brian I. Rini
Vanderbilt University
Affiliation Vanderbilt University Top Publications Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018) – 4,775 citations Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2019) – 3,503 citations Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2019) – 2,599 citations Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell ... <a title="Brian I. Rini" class="read-more" href="https://journalsworld.com/researchers/brian-i-rini/" aria-label="Read more about Brian I. Rini">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Vanderbilt University
Top Publications
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018) - 4,775 citations
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2019) - 3,503 citations
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2019) - 2,599 citations
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study (2009) - 2,169 citations
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (2011) - 1,863 citations
At a glance
- Full name
- Brian I. Rini
- ORCID
- 0000-0002-2212-080X
- OpenAlex ID
- https://openalex.org/A5025529463
Research interests
- Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Ferroptosis and cancer prognosis, Angiogenesis and VEGF in Cancer
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ↗2018 · New England Journal of Medicine4,775OpenAlex citations
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma ↗2019 · New England Journal of Medicine3,503OpenAlex citations
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma ↗2019 · New England Journal of Medicine2,599OpenAlex citations
- 2,169OpenAlex citations
- 1,863OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ↗2018 · New England Journal of Medicine
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma ↗2019 · New England Journal of Medicine
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma ↗2019 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 21:19:17
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.